BRTX
BioRestorative Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.60
+3.90%Year over year
Reported trailing growth
- Revenue
- -8.5%
- EBITDA
- +13.8%
- EBIT
- -16.1%
- EPS
- -62.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +726.3%
- EBITDA
- +89.5%
- EPS
- +93.7%
Three-year CAGR
- Revenue
- +44.3%
- EBITDA
- -59.6%
- EBIT
- -35.4%
- Net income
- -58.6%
- EPS
- -36.2%
- Free cash flow
- -30.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026